A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants
Completed · Phase 1 · NCT05981976
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $63,854
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 174
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Abatacept (biological)
- Dates
- Started 2023-08-18; completion 2023-12-14
- Results posted
- Not yet
The purpose of this study is to compare the relative absorption of abatacept in healthy participants following subcutaneous (SC) administration in which the drug substance is manufactured with the current or new process.
From ClinicalTrials.gov, last updated 2024-07-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $63,854 in research payments for this study in 2025 (2 payments).
Products named: Orencia
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Youngjun Kim, MD Clinical Pharmacology · Cypress, CA
- Kimberly Cruz, M.D. Pediatrics · Pompano Beach, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Vince and Associates Clinical $39,944
- Advanced Pharma Cr, Llc $23,909
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.